Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2026 | Exploring SBRT for patients with localized kidney tumors

Giulio Francolini, MD, University of Florence, Florence, Italy, discusses the potential of stereotactic body radiation therapy (SBRT) for primary kidney cancer, particularly for patients who are poor candidates for partial nephrectomy, highlighting its non-invasive nature and promising rates of local control and low adverse events. SBRT may offer a valuable treatment option for these patients, demonstrating its increased usefulness in the near future. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

This is a very interesting point of view about the Young Academic Urologists group about the use of SBRT for primary kidney cancer. This is a very interesting treatment option, especially for those patients who are poor candidates for partial nephrectomy. It’s a non-invasive treatment option. It may come with an especially high rate of local control and low rate of adverse events after treatment...

This is a very interesting point of view about the Young Academic Urologists group about the use of SBRT for primary kidney cancer. This is a very interesting treatment option, especially for those patients who are poor candidates for partial nephrectomy. It’s a non-invasive treatment option. It may come with an especially high rate of local control and low rate of adverse events after treatment. So it will be, we hope, that it will be very very useful in the near future.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...